Phase 3 LIBERTY-AIMS results showed dupilumab reduced nasal polyp size and sinus symptoms in adults and children with allergic fungal rhinosinusitis.
The FDA has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis.
Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitisApproval in adults and ...
The approval makes Dupixent the first FDA-approved therapy for allergic fungal rhinosinusitis, supported by Phase III data showing significant improvements in sinus opacification, nasal symptoms, and ...
The FDA has approved dupilumab to treat allergic fungal rhinosinusitis in adults and children ages 6 years and older.
MedPage Today on MSN
FDA Approves First Drug for Allergic Fungal Rhinosinusitis
Indication covers kids and adults with a history of sino-nasal surgery ...
A ratio of sinus scores calculated based on computed tomography (CT) imaging can accurately predict the recurrence of chronic rhinosinusitis (CRS) with nasal polyps, according to new findings. A ratio ...
Add Yahoo as a preferred source to see more of our stories on Google. It's respiratory virus season — and between RSV, the flu and COVID-19, there’s no shortage of contagious viruses making people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results